


 Cite this: *RSC Adv.*, 2020, 10, 12135

6,*N*²-Diaryl-1,3,5-triazine-2,4-diamines: synthesis, antiproliferative activity and 3D-QSAR modeling†

 Ahmad Junaid,^a Felicia Phei Lin Lim,^a Lay Hong Chuah^a
 and Anton V. Dolzhenko^{id}*^{ab}

A library of 126 compounds with a 6,*N*²-diaryl-1,3,5-triazine-2,4-diamine scaffold was prepared using a one-pot, microwave-assisted method from readily available cyanoguanidine, aromatic aldehydes and arylamines. The three-component condensation of these reagents in the presence of hydrochloric acid was followed by the treatment with a base, which promoted a rearrangement of the dihydrotriazine ring and its dehydrogenative aromatization. The antiproliferative properties of the prepared compounds were evaluated using three breast cancer cell lines. The most promising results were obtained in the growth inhibition of the triple negative MDA-MB231 breast cancer cells. The active compounds were also selective against cancer cells and did not affect growth of the non-cancerous MCF-10A breast cell line. Analyzing the structure–activity relationship within the series, we built a 3D-QSAR model for the further design of more potent anticancer compounds.

 Received 21st January 2020
 Accepted 13th March 2020

DOI: 10.1039/d0ra00643b

rsc.li/rsc-advances

Introduction

The 1,3,5-triazine ring has been extensively explored as a scaffold for the design and construction of molecules with therapeutically useful properties.¹ Particular advancements were made in the area of the anticancer agent development.² Several 1,3,5-triazine based agents have been used for the treatment of various types of cancer, from earlier developed alkylating agents tretamine^{3,4} and altretamine⁵ to nucleic acid targeting nucleosides azacitidine⁶ and decitabine,^{7,8} and a recently approved inhibitor of isocitrate dehydrogenase 2, mesenidenib^{9,10} (Fig. 1). An intensive exploration of the 1,3,5-triazine scaffold has continued and a number of notable anticancer 1,3,5-triazines have been recently developed, including those undergoing clinical trials gedatolisib inhibiting PI3K and mTOR kinases,^{11,12} PAK4 inhibitor KY-04031 effective against prostate cancer,¹³ and HL010183 particularly effective in the inhibition of proliferation and invasion of triple-negative breast cancer cells.^{14,15}

Recently we reported a new effective synthesis of a library of 6,*N*²-diaryl-1,3,5-triazine-2,4-diamines, some of which demonstrated promising anticancer properties in preliminary assessment on the DU145 prostate cancer cell line.¹⁶ Inspired by these

results, we further expanded the initial library to 126 compounds and performed antiproliferative screening of these compounds on three types of breast cancer cell lines. Herein, we report result of this work and attempt to build a QSAR model for the further design of more active compounds.

Results and discussion

Synthesis

The microwave-assisted synthesis has been recognized as a highly valuable approach for the synthesis of 1,3,5-triazines.¹⁷ We applied focused microwave irradiation for the synthesis of 6,*N*²-diaryl-1,3,5-triazine-2,4-diamines using a recently developed one-pot method.¹⁶ Initially, a three-component reaction of cyanoguanidine, aromatic aldehydes and arylamines was carried out in the presence of hydrochloric acid under microwave irradiation. Without isolation, intermediates **I** were treated with a base to give products of the Dimroth rearrangement **II**, which, at the reaction conditions, underwent a spontaneous dehydrogenation and aromatization affording desired 6,*N*²-diaryl-1,3,5-triazine-2,4-diamines (**1–126**) (Scheme 1).

The developed protocol for the synthesis of 6,*N*²-diaryl-1,3,5-triazine-2,4-diamines (**1–126**) was rather general and convenient for the generation of libraries covering a sufficiently broad chemical space for the biological screening.

Cytotoxic evaluation

The prepared compounds **1–126** were tested on three breast cancer cell lines namely, MDA-MB231, SKBR-3 and MCF-7 using MTT assay. SKBR-3 and MCF-7 cell lines are estrogen and progesterone hormone positive cell lines often used as a model

^aSchool of Pharmacy, Monash University Malaysia, Jalan Lagoon Selatan, Bandar Sunway, Selangor Darul Ehsan 47500, Malaysia. E-mail: anton.dolzhenko@monash.edu

^bSchool of Pharmacy and Biomedical Sciences, Curtin Health Innovation Research Institute, Faculty of Health Sciences, Curtin University, GPO Box U1987, Perth, Western Australia 6845, Australia

† Electronic supplementary information (ESI) available: Copies of ¹H and ¹³C NMR spectra of new compounds and concentration–response plots used for the calculation GI₅₀ values. See DOI: 10.1039/d0ra00643b







Fig. 1 Selected anticancer 1,3,5-triazines.


for the hormone therapy.¹⁸ MDA-MB231 is triple negative breast cancer cell line, which is negative to estrogen and progesterone receptors and human epidermal growth factor receptor 2, a perfect model for chemotherapy.¹⁸ Initially, all the prepared

compounds 1–126 were tested on these three cancer cell lines at the screening concentration (10 μ M) and percentage of cell viability was calculated 72 h after the treatment (Table 1).




Scheme 1 Synthesis of 6,*N*²-diaryl-1,3,5-triazine-2,4-diamines (1–126).



Table 1 Antiproliferative screening of 6,*N*²-diaryl-1,3,5-triazine-2,4-diamines (1–126) at 10 μM


Compd	R ¹	R ²	Percentage of cell viability ^a		
			MDA-MB231	SKBR-3	MCF-7
1	Ph	Ph	87	81	90
2	Ph	2-FC ₆ H ₄	82	83	99
3	Ph	4-FC ₆ H ₄	81	84	100
4	Ph	2-ClC ₆ H ₄	72	88	81
5	Ph	4-ClC ₆ H ₄	65	94	100
6	Ph	4-BrC ₆ H ₄	65	97	100
7	Ph	4-MeC ₆ H ₄	98	87	87
8	Ph	2-MeOC ₆ H ₄	78	97	91
9	Ph	4-MeOC ₆ H ₄	98	96	84
10	Ph	4-CF ₃ OC ₆ H ₄	96	86	92
11	Ph	4-iPrC ₆ H ₄	99	86	99
12	Ph	3-Pyridyl	59	78	87
13	3-FC ₆ H ₄	Ph	100	100	89
14	3-FC ₆ H ₄	4-FC ₆ H ₄	50	100	78
15	3-FC ₆ H ₄	4-ClC ₆ H ₄	100	100	89
16	3-FC ₆ H ₄	4-BrC ₆ H ₄	43	89	80
17	3-FC ₆ H ₄	4-MeC ₆ H ₄	29	90	71
18	3-FC ₆ H ₄	4-MeOC ₆ H ₄	46	74	76
19	3-FC ₆ H ₄	4-CF ₃ OC ₆ H ₄	50	100	76
20	3-FC ₆ H ₄	4-iPrC ₆ H ₄	100	100	92
21	4-FC ₆ H ₄	Ph	83	94	100
22	4-FC ₆ H ₄	2-FC ₆ H ₄	83	85	100
23	4-FC ₆ H ₄	4-FC ₆ H ₄	81	100	93
24	4-FC ₆ H ₄	2-ClC ₆ H ₄	75	75	91
25	4-FC ₆ H ₄	3-ClC ₆ H ₄	73	88	95
26	4-FC ₆ H ₄	4-ClC ₆ H ₄	67	98	87
27	4-FC ₆ H ₄	4-BrC ₆ H ₄	96	100	94
28	4-FC ₆ H ₄	4-MeC ₆ H ₄	99	90	88
29	4-FC ₆ H ₄	2-MeOC ₆ H ₄	60	81	96
30	4-FC ₆ H ₄	4-MeOC ₆ H ₄	74	90	92
31	4-FC ₆ H ₄	4-CF ₃ OC ₆ H ₄	88	92	87
32	4-FC ₆ H ₄	4-iPrC ₆ H ₄	94	100	84
33	4-FC ₆ H ₄	3-Pyridyl	74	87	85
34	4-ClC ₆ H ₄	Ph	81	100	100
35	4-ClC ₆ H ₄	2-FC ₆ H ₄	82	99	93
36	4-ClC ₆ H ₄	4-FC ₆ H ₄	49	98	100
37	4-ClC ₆ H ₄	2-ClC ₆ H ₄	99	89	99
38	4-ClC ₆ H ₄	3-ClC ₆ H ₄	99	92	84
39	4-ClC ₆ H ₄	4-ClC ₆ H ₄	97	100	100
40	4-ClC ₆ H ₄	4-BrC ₆ H ₄	80	100	92
41	4-ClC ₆ H ₄	2-MeOC ₆ H ₄	83	89	100
42	4-ClC ₆ H ₄	4-MeOC ₆ H ₄	61	90	85
43	4-ClC ₆ H ₄	4-CF ₃ OC ₆ H ₄	93	83	100
44	4-ClC ₆ H ₄	4-iPrC ₆ H ₄	100	97	96
45	4-ClC ₆ H ₄	3-Pyridyl	99	74	89
46	4-BrC ₆ H ₄	2-FC ₆ H ₄	75	91	100
47	4-BrC ₆ H ₄	4-FC ₆ H ₄	58	98	100
48	4-BrC ₆ H ₄	2-ClC ₆ H ₄	90	93	100
49	4-BrC ₆ H ₄	4-ClC ₆ H ₄	96	100	100
50	4-BrC ₆ H ₄	4-MeC ₆ H ₄	55	93	88
51	4-BrC ₆ H ₄	2-MeOC ₆ H ₄	88	89	96
52	4-BrC ₆ H ₄	4-MeOC ₆ H ₄	56	91	100


Table 1 (Contd.)



Compd	R ¹	R ²	Percentage of cell viability ^a		
			MDA-MB231	SKBR-3	MCF-7
53	3-MeC ₆ H ₄	4-FC ₆ H ₄	100	100	78
54	3-MeC ₆ H ₄	4-ClC ₆ H ₄	100	93	76
55	3-MeC ₆ H ₄	4-BrC ₆ H ₄	83	96	75
56	3-MeC ₆ H ₄	4-MeC ₆ H ₄	12	62	67
57	3-MeC ₆ H ₄	4-MeOC ₆ H ₄	91	90	75
58	3-MeC ₆ H ₄	4-CF ₃ OC ₆ H ₄	50	100	73
59	3-MeC ₆ H ₄	4-iPrC ₆ H ₄	87	93	76
60	4-MeC ₆ H ₄	Ph	84	100	100
61	4-MeC ₆ H ₄	2-FC ₆ H ₄	50	79	73
62	4-MeC ₆ H ₄	4-FC ₆ H ₄	48	78	100
63	4-MeC ₆ H ₄	4-BrC ₆ H ₄	87	100	93
64	4-MeC ₆ H ₄	4-MeC ₆ H ₄	59	92	86
65	4-MeC ₆ H ₄	2-MeOC ₆ H ₄	97	88	87
66	4-MeC ₆ H ₄	4-MeOC ₆ H ₄	83	89	100
67	4-MeC ₆ H ₄	4-CF ₃ OC ₆ H ₄	92	84	93
68	4-MeC ₆ H ₄	4-iPrC ₆ H ₄	76	91	100
69	4-MeC ₆ H ₄	3-Pyridyl	74	79	88
70	4-MeOC ₆ H ₄	2-FC ₆ H ₄	9	46	63
71	4-MeOC ₆ H ₄	4-MeOC ₆ H ₄	56	93	95
72	4-MeOC ₆ H ₄	4-FC ₆ H ₄	68	100	100
73	4-MeOC ₆ H ₄	2-ClC ₆ H ₄	10	47	84
74	4-MeOC ₆ H ₄	3-ClC ₆ H ₄	22	45	86
75	4-MeOC ₆ H ₄	4-ClC ₆ H ₄	99	100	100
76	4-MeOC ₆ H ₄	4-BrC ₆ H ₄	96	100	91
77	4-MeOC ₆ H ₄	3-MeC ₆ H ₄	22	40	79
78	4-MeOC ₆ H ₄	2-MeOC ₆ H ₄	50	66	57
79	4-MeOC ₆ H ₄	4-CF ₃ OC ₆ H ₄	74	84	95
80	4-MeOC ₆ H ₄	4-iPrC ₆ H ₄	92	86	100
81	4-MeOC ₆ H ₄	3-Pyridyl	46	77	91
82	4-CF ₃ C ₆ H ₄	Ph	55	97	96
83	4-CF ₃ C ₆ H ₄	2-FC ₆ H ₄	55	71	93
84	4-CF ₃ C ₆ H ₄	4-FC ₆ H ₄	95	98	100
85	4-CF ₃ C ₆ H ₄	4-ClC ₆ H ₄	90	77	99
86	4-CF ₃ C ₆ H ₄	4-MeC ₆ H ₄	54	95	83
87	4-CF ₃ C ₆ H ₄	2-MeOC ₆ H ₄	63	85	100
88	4-CF ₃ C ₆ H ₄	4-MeOC ₆ H ₄	81	86	100
89	4-CF ₃ OC ₆ H ₄	Ph	59	90	95
90	4-CF ₃ OC ₆ H ₄	2-FC ₆ H ₄	60	80	90
91	4-CF ₃ OC ₆ H ₄	4-FC ₆ H ₄	53	86	100
92	4-CF ₃ OC ₆ H ₄	2-ClC ₆ H ₄	74	86	96
93	4-CF ₃ OC ₆ H ₄	4-BrC ₆ H ₄	83	96	90
94	4-CF ₃ OC ₆ H ₄	4-MeC ₆ H ₄	79	87	97
95	4-CF ₃ OC ₆ H ₄	2-MeOC ₆ H ₄	46	81	88
96	4-CF ₃ OC ₆ H ₄	4-MeOC ₆ H ₄	69	88	87
97	4-CF ₃ OC ₆ H ₄	4-CF ₃ OC ₆ H ₄	92	80	100
98	4-CF ₃ OC ₆ H ₄	4-iPrC ₆ H ₄	100	90	95
99	4-CF ₃ OC ₆ H ₄	3-Pyridyl	33	81	85
100	4-Me ₂ NC ₆ H ₄	Ph	21	61	80
101	4-Me ₂ NC ₆ H ₄	2-FC ₆ H ₄	28	51	88
102	4-Me ₂ NC ₆ H ₄	4-FC ₆ H ₄	32	88	90
103	4-Me ₂ NC ₆ H ₄	2-MeOC ₆ H ₄	28	48	88
104	4-Me ₂ NC ₆ H ₄	4-iPrC ₆ H ₄	70	87	100



Table 1 (Contd.)



Compd	R ¹	R ²	Percentage of cell viability ^a		
			MDA-MB231	SKBR-3	MCF-7
105	4- <i>t</i> BuC ₆ H ₄	Ph	74	100	96
106	4- <i>t</i> BuC ₆ H ₄	4-FC ₆ H ₄	97	84	88
107	4- <i>t</i> BuC ₆ H ₄	4-ClC ₆ H ₄	100	92	98
108	4- <i>t</i> BuC ₆ H ₄	4-BrC ₆ H ₄	59	98	99
109	4- <i>t</i> BuC ₆ H ₄	4-MeOC ₆ H ₄	91	85	93
110	4-BnOC ₆ H ₄	Ph	51	75	100
111	4-BnOC ₆ H ₄	4-FC ₆ H ₄	69	84	89
112	4-BnOC ₆ H ₄	4-BrC ₆ H ₄	82	93	97
113	4-BnOC ₆ H ₄	4-MeC ₆ H ₄	82	94	100
114	4-BnOC ₆ H ₄	4-CF ₃ OC ₆ H ₄	71	87	100
115	2-Thienyl	Ph	100	87	91
116	2-Thienyl	2-FC ₆ H ₄	98	78	90
117	2-Thienyl	4-FC ₆ H ₄	100	86	92
118	2-Thienyl	2-ClC ₆ H ₄	100	78	91
119	2-Thienyl	4-ClC ₆ H ₄	100	89	98
120	2-Thienyl	4-BrC ₆ H ₄	46	87	88
121	2-Thienyl	4-MeC ₆ H ₄	49	95	97
122	2-Thienyl	2-MeOC ₆ H ₄	78	97	91
123	2-Thienyl	4-MeOC ₆ H ₄	93	88	80
124	2-Thienyl	4-CF ₃ OC ₆ H ₄	100	86	85
125	2-Thienyl	4- <i>i</i> PrC ₆ H ₄	100	86	89
126	2-Thienyl	3-Pyridyl	100	91	86

^a Mean of three independent experiments.

The prepared 6,*N*²-diaryl-1,3,5-triazine-2,4-diamines selectively inhibited the triple negative breast cancer cells. It was observed that hormone independent cell line (MDA-MB231) was generally more sensitive to the treatment with 6,*N*²-diaryl-1,3,5-triazine-2,4-diamines, whereas hormone dependent cancer cell lines (SKBR-3 and MCF-7) were more resistant to the treatment with these compounds.

Compounds reducing the growth of the MDA-MB231 cancer cells (at concentration 10 μM) to 50% or less were selected for the evaluation of their 50% growth inhibitory concentrations (GI₅₀). The growth inhibitory effect of the compounds was determined on breast tumor cell line (MDA-MB231, SKBR-3 and MCF-7) at different concentrations with methotrexate and nilotinib as positive controls (Table 2). All the tested compounds were more effective towards the MDA-MB231 cancer cell line than SKBR-3 and MCF-7 cells.

Analysis of the structure-activity relationship identified a pattern in types and combinations of R¹ and R² groups associated with the antiproliferative effect. In general, replacement of a phenyl at R¹ with the 2-thienyl moiety or a phenyl at R² with the 3-pyridyl ring demonstrated only slight or no improvement in the

cell growth inhibition. Analyzing effect of the substituent at the phenyl rings, we found that antiproliferative properties typically required +M electron-donating groups in *para*-position of the R¹ phenyl ring or a *meta*-substitution in the same ring. The tolerance of the activity to the R² substituents depended on the type of the R¹ substitution. The combination of a *para*-substituted phenyl as R¹ with the *para*-substituted phenyl as R² was detrimental for the activity (except R² = 4-FC₆H₄). However, the antiproliferative effect of compounds with a *meta*-substituted phenyl as R¹ was less sensitive to the position of substituents in the R² moiety. These compounds retained good antiproliferative effect with the *para*-substituted phenyl as the R² group. The most efficient for the antiproliferative activity against MDA-MB231 cells were combinations of *para*-methoxy or *para*-dimethylamino groups in the R¹ phenyl ring and *ortho*-fluoro- or *ortho*-chlorophenyl group as R² (compounds 70, 73, and 101). These compounds were also very active against SKBR-3 cells. Moreover, compound 73 was equipotent in the inhibition of MDA-MB231 and SKBR-3 cell growth. Compound 101 was identified as the most active among the tested compounds in its cytotoxic effect against MDA-MB231 cells with GI₅₀ value of 0.06 μM.

All the compounds, selected for determination of GI₅₀ values against MDA-MB231 cells, were also used for the experiments with MCF-10A normal breast cells. None of the tested compounds applied at concentration of 25 μM showed significant inhibition of the normal breast cell growth. These results indicated that the tested compounds were selectively active towards the breast cancer cells without any substantial effects on the normal breast cells.


3D-QSAR study

To comprehend the structural requirement controlling the antiproliferative activity, a 3D-QSAR model was built applying 3D-QSAR protocol of Discovery Studio v18 (ref. 19) to the experimentally obtained biological data. Twenty-five compounds, having GI₅₀ values against MDA-MB231 breast cancer cell line in the range of 0.06 μM to 15.24 μM, were selected as model data set. The GI₅₀ values of the compounds were converted into corresponding pGI₅₀ values (-log[GI₅₀]) using 'Prepare dependent values' protocol in Discovery Studio. The compounds were initially aligned to the minimum energy and then randomly divided into training set (~80%) and test set (~20%) by 'Diverse molecule' method in Discovery Studio.

The QSAR model was built using 'Create 3D-QSAR model' protocol in Discovery Studio. The correlation coefficient *r*² between the observed and predicted pGI₅₀ values of the training set was found to be 0.81 proving acceptability of the built QSAR model. RMSE residual error was found to be 0.31 indicating a good ability of the built model to predict the GI₅₀ values. The *r*² value > 0.5 and RMSE residual error < 0.5 were considered to represent good model.^{20,21} Graphically, the model predictive potential is represented by the plot of the experimental pGI₅₀ versus predicted pGI₅₀ values (Fig. 2). The pGI₅₀ values predicted by this QSAR model and the residual errors for all 25 compounds are presented in Table 3.



Table 2 Inhibition of cell growth by compounds selected after the initial screening



Compound	R ¹	R ²	GI ₅₀ ^a (μM) ± SEM ^b			
			MDA-MB231	SKBR-3	MCF-7	MCF-10A
14	3-FC ₆ H ₄	4-FC ₆ H ₄	9.21 ± 0.38	>20	>20	>25
16	3-FC ₆ H ₄	4-BrC ₆ H ₄	13.13 ± 0.91	17.16 ± 1.07	>20	>25
17	3-FC ₆ H ₄	4-MeC ₆ H ₄	3.96 ± 0.17	>20	>20	>25
18	3-FC ₆ H ₄	4-MeOC ₆ H ₄	6.18 ± 0.43	16.63 ± 1.38	>20	>25
19	3-FC ₆ H ₄	4-CF ₃ OC ₆ H ₄	8.56 ± 0.59	>20	18.22 ± 1.28	>25
36	4-ClC ₆ H ₄	4-FC ₆ H ₄	14.14 ± 1.52	19.40 ± 2.39	>20	>25
56	3-MeC ₆ H ₄	4-MeC ₆ H ₄	0.17 ± 0.02	1.26 ± 0.18	>20	>25
58	3-MeC ₆ H ₄	4-CF ₃ OC ₆ H ₄	15.24 ± 1.01	>20	>20	>25
61	4-MeC ₆ H ₄	2-FC ₆ H ₄	12.25 ± 1.15	>20	>20	>25
62	4-MeC ₆ H ₄	4-FC ₆ H ₄	10.68 ± 0.73	>20	20.15 ± 1.95	>25
70	4-MeOC ₆ H ₄	2-FC ₆ H ₄	0.32 ± 0.04	>20	>20	>25
73	4-MeOC ₆ H ₄	2-ClC ₆ H ₄	0.23 ± 0.03	1.10 ± 0.01	>20	>25
74	4-MeOC ₆ H ₄	3-ClC ₆ H ₄	1.33 ± 0.17	0.18 ± 0.04	18.30 ± 1.11	>25
77	4-MeOC ₆ H ₄	3-MeC ₆ H ₄	0.95 ± 0.04	3.38 ± 0.36	>20	>25
78	4-MeOC ₆ H ₄	2-MeOC ₆ H ₄	13.25 ± 0.93	2.15 ± 0.12	>20	>25
81	4-MeOC ₆ H ₄	3-Pyridyl	14.01 ± 1.33	15.58 ± 1.06	>20	>25
95	4-CF ₃ OC ₆ H ₄	2-MeOC ₆ H ₄	12.77 ± 0.76	>20	>20	>25
99	4-CF ₃ OC ₆ H ₄	3-Pyridyl	11.52 ± 1.51	>20	>20	>25
100	4-Me ₂ NC ₆ H ₄	Ph	0.36 ± 0.07	4.19 ± 0.37	>20	>25
101	4-Me ₂ NC ₆ H ₄	2-FC ₆ H ₄	0.06 ± 0.001	0.29 ± 0.04	>20	>25
102	4-Me ₂ NC ₆ H ₄	4-FC ₆ H ₄	7.20 ± 0.94	>20	>20	>25
103	4-Me ₂ NC ₆ H ₄	2-MeOC ₆ H ₄	4.17 ± 0.33	3.63 ± 0.23	>20	>25
110	4-BnOC ₆ H ₄	Ph	13.44 ± 1.18	>20	>20	>25
120	2-Thienyl	4-BrC ₆ H ₄	11.73 ± 1.39	>20	>20	>25
121	2-Thienyl	4-MeC ₆ H ₄	13.88 ± 1.74	>20	>20	>25
Metotrexate ^c			0.01 ± 0.001	ND	5.79 ± 0.47	ND
Nilotinib ^c			0.04 ± 0.001	9.60 ± 0.51	ND	ND

^a Concentration (μM) required to inhibit tumor cell growth by 50%, values are mean of three independent experiments. ^b Standard error of the mean. ^c Positive controls, ND = not determined.

The molecules aligned to the iso-surface of 3D-QSAR model on electrostatic potential grid and van der Waals grid are shown in Fig. 3. Red colour in the electrostatic grid (Fig. 3A) symbolizes that an increase in electron density in this region should increase the activity, while blue colour represents area where lower electron density is expected to be beneficial for the activity. Likewise, green contour in steric map (Fig. 3B) indicates a potential increase in the activity with sterically bulky groups in these regions, while yellow contour shows areas where an increase in the steric bulk would result in a lower activity.²¹

The 3D-QSAR map suggested that compounds bearing a high electron density and bulky group at R¹ position would show higher activity. Despite the high residual error (0.69) observed for compound **101**, this 3D-QSAR map validated its highest activity as the dimethylamino group at the R¹ phenyl ring clearly met the above description, particularly on the electrostatic grid.

The good antiproliferative activity of compounds bearing a *para*-methoxy group at the R¹ phenyl was also well aligned with the model. The positioning of the most active in the series compound **101** (GI₅₀ = 0.06 μM) in the electrostatic and van der Waals grids is shown in Fig. 4.

Conclusions

We synthesized a library of 6, N²-diaryl-1,3,5-triazine-2,4-diamines and evaluated their antiproliferative properties against three breast cancer cell lines. It was found that MDA-MB231 triple negative breast cancer cells were more sensitive to the prepared compounds than SKBR-3 and MCF-7 cells. The active compounds also demonstrated no inhibition on the growth of non-cancerous MCF-10A breast cells. The 3D-QSAR model constructed using the obtained data could be used for the further design of compound-targeting triple negative breast cancer cells.






Fig. 2 Plot of experimental versus predicted pGI₅₀ activity of training set.

Table 3 Experimental and predicted by 3D-QSAR model inhibitory activities of compounds^a

Compound	Experimental pGI ₅₀	Predicted pGI ₅₀	Residual error
14	5.04	5.33	-0.30
16	4.88	4.90	-0.01
17	5.40	5.26	0.15
18	5.21	5.46	-0.25
19	5.07	5.01	0.06
36	4.85	5.04	-0.19
56	6.77	6.31	0.46
<u>58</u>	4.82	5.23	-0.41
61	4.91	5.40	-0.49
62	4.97	4.89	0.08
70	6.49	5.85	0.64
<u>73</u>	6.64	6.10	0.54
74	5.88	6.16	-0.29
77	6.02	6.03	-0.01
<u>78</u>	4.88	5.78	-0.90
71	4.85	5.29	-0.43
95	4.89	5.16	-0.27
<u>99</u>	4.94	4.28	0.66
100	6.44	6.27	0.17
<u>101</u>	7.22	6.55	0.67
102	5.14	5.04	0.10
103	5.38	5.29	0.09
110	4.87	5.07	-0.20
<u>120</u>	4.93	4.46	0.47
121	4.86	4.82	0.04

^a Underlined compounds were randomly selected for test set.

Experimental

General

Melting points (uncorrected) were determined on a StuartTM SMP40 automatic melting point apparatus. ¹H and ¹³C NMR




Fig. 3 3D-QSAR model coefficients on electrostatic grid (A) and van der Waals grid (B).

spectra were recorded on a Bruker Fourier NMR spectrometer (300 MHz) using DMSO-*d*₆ as a solvent and TMS as an internal reference. Microwave-assisted reactions were carried out in the closed vessel focused single mode using a Discover SP microwave synthesizer (CEM, USA) monitoring reaction temperature by the equipped IR sensor. The synthesis of compounds 1, 5–29, 31–33, 35–52, 54–56, 58, 60–64, 66–70, 72–83, 85–90, 92–110, 112–115, 117–121, 124–126 and their characterization were described earlier.¹⁶






Fig. 4 3D-QSAR model coefficients of compound 101 on electrostatic grid (A) and van der Waals grid (B).

General method for the synthesis of 6,*N*²-diaryl-1,3,5-triazine-2,4-diamines (1–126)

To a solution of cyanoguanidine (0.21 g, 2.5 mmol), an aromatic aldehyde (2.5 mmol) and an arylamine (2.5 mmol) in EtOH (2 mL) in a 10 mL seamless pressure vial, conc. HCl (0.21 mL, 2.5 mmol) was added. The reaction mixture was heated at 140 °C for 50 min by irradiation in the Discover SP (CEM) microwave reactor operating at maximal microwave power up to 150 W.

Then, an aq. solution of NaOH (5 N, 1 mL) was added to the reaction mixture and heating was continued for another 15 min at 140 °C. After cooling, the precipitated product was filtered, washed with water and recrystallized from a suitable solvent.

*N*²-(2-Fluorophenyl)-6-phenyl-1,3,5-triazine-2,4-diamine (2)

Yield 0.12 g, 30%. Mp 156–158 °C (EtOH). ¹H NMR (300 MHz, DMSO-*d*₆): δ 7.08 (2H, brs, NH₂), 7.17–7.30 (3H, m, H-3'', H-4'' and H-5''), 7.46–7.54 (3H, m, H-3', H-4' and H-5'), 7.75–7.81 (1H, m, H-6''), 8.28 (2H, dd, *J* = 1.6 Hz, *J* = 8.1 Hz, H-2' and H-6'), 9.02 (1H, s, NH); ¹³C NMR (75 MHz, DMSO-*d*₆): δ 115.5 (d, ²*J*_{CF} = 19.4 Hz, C-3''), 124.0 (d, ³*J*_{CF} = 3.7 Hz, C-6''), 125.5 (d, ³*J*_{CF} = 7.5 Hz, C-4''), 126.6 (d, ⁴*J*_{CF} = 1.5 Hz, C-5''), 126.7 (d, ²*J*_{CF} = 12.0 Hz, C-1''), 127.7 (C-3' and C-5'), 128.2 (C-2' and C-6'), 131.3 (C-4'), 136.6 (C-1'), 155.4 (d, ¹*J*_{CF} = 245.9 Hz, C-2''), 165.2 (C-4), 167.3 (C-6), 170.2 (C-2). Anal. calcd for C₁₅H₁₂FN₅: C, 64.05; H, 4.30; N, 24.90. Found: C, 63.96; H, 4.41; N, 24.77.

*N*²-(4-Fluorophenyl)-6-phenyl-1,3,5-triazine-2,4-diamine (3)

Yield 0.25 g, 37%. Mp 172–174 °C (EtOH). ¹H NMR (300 MHz, DMSO-*d*₆): δ 7.13 (2H, brs, NH₂), 7.15 (2H, dd, ³*J*_{HF} = 8.8 Hz, ³*J*_{HH} = 9.2 Hz, H-3'' and H-5''), 7.48–7.56 (3H, m, H-3', H-4' and H-5'), 7.85 (2H, dd, ⁴*J*_{HF} = 5.0 Hz, ³*J*_{HH} = 9.2 Hz, H-2'' and H-6''), 8.32 (2H, dd, *J* = 1.7 Hz, *J* = 8.1 Hz, H-2' and H-6'), 9.57 (1H, s, NH); ¹³C NMR (75 MHz, DMSO-*d*₆): δ 114.9 (d, ²*J*_{CF} = 22.0 Hz, C-3'' and C-5''), 121.6 (d, ³*J*_{CF} = 8.2 Hz, C-2'' and C-6''), 127.7 (C-3' and C-5'), 128.2 (C-2' and C-6'), 131.3 (C-4'), 136.2 (d, ⁴*J*_{CF} = 2.2 Hz, C-1''), 136.7 (C-1'), 157.4 (d, ¹*J*_{CF} = 238.6 Hz, C-4''), 164.5 (C-4), 167.1 (C-6), 170.2 (C-2). Anal. calcd for C₁₅H₁₂FN₅: C, 64.05; H, 4.30; N, 24.90. Found: C, 63.97; H, 4.38; N, 24.81.

*N*²-(2-Chlorophenyl)-6-phenyl-1,3,5-triazine-2,4-diamine (4)

Yield 0.26 g, 35%. Mp 82–84 °C (EtOH/H₂O). ¹H NMR (300 MHz, DMSO-*d*₆): δ 7.10 (2H, brs, NH₂), 7.20 (1H, ddd, *J* = 1.6 Hz, *J* = 7.5 Hz, *J* = 7.9 Hz, H-4''), 7.37 (1H, ddd, *J* = 1.5 Hz, *J* = 7.5 Hz, *J* = 8.0 Hz, H-5''), 7.46–7.54 (4H, m, H-3', H-5', H-4' and H-3''), 7.84 (1H, dd, *J* = 1.6 Hz, *J* = 8.0 Hz, H-6''), 8.26 (2H, dd, *J* = 1.6 Hz, *J* = 6.7 Hz, H-2' and H-6'), 8.75 (1H, s, NH); ¹³C NMR (75 MHz, DMSO-*d*₆): δ 125.9 (C-6''), 127.1 (C-4''), 127.3 (C-2''), 127.7 (C-3' and C-5'), 128.0 (C-5''), 128.2 (C-2' and C-6'), 129.3 (C-3''), 131.3 (C-4'), 135.7 (C-1''), 136.5 (C-1'), 165.1 (C-4), 167.2 (C-6), 170.2 (C-2). Anal. calcd for C₁₅H₁₂ClN₅: C, 60.51; H, 4.06; N, 23.52. Found: C, 60.39; H, 4.15; N, 23.44.

6-(4-Fluorophenyl)-*N*²-(4-methoxyphenyl)-1,3,5-triazine-2,4-diamine (30)

Yield 0.20 g, 30%. Mp 158–160 °C (MeCN). ¹H NMR (300 MHz, DMSO-*d*₆): δ 3.75 (3H, s, OCH₃), 6.91 (2H, d, *J* = 9.0 Hz, H-3'' and H-5''), 7.06 (2H, brs, NH₂), 7.33 (2H, dd, ³*J*_{HF} = 9.0 Hz, ³*J*_{HH} = 8.8 Hz, H-3' and H-5'), 7.70 (2H, d, *J* = 8.9 Hz, H-2'' and H-6''), 8.36 (2H, dd, ⁴*J*_{HF} = 5.8 Hz, ³*J*_{HH} = 8.8 Hz, H-2' and H-6'), 9.37 (1H, s, NH); ¹³C NMR (75 MHz, DMSO-*d*₆): δ 55.1 (OCH₃), 113.6 (C-3'' and C-5''), 115.1 (d, ²*J*_{CF} = 21.7 Hz, C-3' and C-5'), 121.8 (C-2'' and C-6''), 130.1 (d, ³*J*_{CF} = 8.9 Hz, C-2' and C-6'), 132.8 (C-1''), 133.3 (d, ⁴*J*_{CF} = 2.7 Hz, C-1'), 154.7 (C-4''), 164.1 (d, ¹*J*_{CF} =



248.3 Hz, C-4'), 164.4 (C-4), 167.1 (C-6), 169.1 (C-2). Anal. calcd for C₁₆H₁₄FN₅O: C, 61.73; H, 4.53; N, 22.50. Found: C, 61.60; H, 4.65; N, 22.34.

6-(4-Chlorophenyl)-N²-phenyl-1,3,5-triazine-2,4-diamine (34)

Yield 0.25 g, 33%. Mp 154–156 °C (EtOH). ¹H NMR (300 MHz, DMSO-*d*₆): δ 7.01 (1H, t, *J* = 7.9 Hz, H-4''), 7.19 (2H, brs, NH₂), 7.32 (2H, t, *J* = 7.9 Hz, H-3'' and H-5''), 7.60 (2H, d, *J* = 8.6 Hz, H-3' and H-5'), 7.85 (2H, d, *J* = 7.9 Hz, H-2'' and H-6''), 8.33 (2H, d, *J* = 8.7 Hz, H-2' and H-6'), 9.58 (1H, s, NH); ¹³C NMR (75 MHz, DMSO-*d*₆): δ 120.0 (C-2'' and C-6''), 122.0 (C-1''), 128.4 (C-3', C-5', C-3'' and C-5''), 129.5 (C-2' and C-6'), 135.6 (C-1'), 136.1 (C-4'), 139.8 (C-4''), 164.5 (C-4), 167.1 (C-6), 169.2 (C-2). Anal. calcd for C₁₅H₁₂ClN₅: C, 60.51; H, 4.06; N, 23.52. Found: C, 60.46; H, 4.20; N, 23.36.

N²-(4-Fluorophenyl)-6-(3-methylphenyl)-1,3,5-triazine-2,4-diamine (53)

Yield 0.25 g, 35%. Mp 138–139 °C (EtOH/H₂O). ¹H NMR (300 MHz, DMSO-*d*₆): δ 2.40 (3H, s, CH₃), 7.13 (2H, brs, NH₂), 7.15 (2H, dd, ³*J*_{HF} = 8.9 Hz, ³*J*_{HH} = 8.9 Hz, H-3'' and H-5''), 7.37–7.42 (2H, m, H-4' and H-5'), 7.85 (2H, dd, ⁴*J*_{HF} = 5.0 Hz, ³*J*_{HH} = 9.1 Hz, H-2'' and H-6''), 8.10–8.16 (2H, m, H-2' and H-6'), 9.56 (1H, s, NH); ¹³C NMR (75 MHz, DMSO-*d*₆): δ 21.0 (CH₃), 114.8 (d, ²*J*_{CF} = 21.6 Hz, C-2'' and C-6''), 121.5 (d, ³*J*_{CF} = 7.5 Hz, C-3'' and C-5''), 124.9 (C-2'), 128.1 (C-6'), 128.3 (C-5'), 131.9 (C-4'), 136.3 (d, ⁴*J*_{CF} = 3.0 Hz, C-1''), 136.7 (C-3'), 137.3 (C-1'), 157.4 (d, ¹*J*_{CF} = 238.4 Hz, C-4''), 164.4 (C-2), 167.1 (C-4), 170.2 (C-6). Anal. calcd for C₁₆H₁₄FN₅: C, 65.07; H, 4.78; N, 23.71. Found: C, 64.95; H, 4.91; N, 23.58.

N²-(4-Methoxyphenyl)-6-(3-methylphenyl)-1,3,5-triazine-2,4-diamine (57)

Yield 0.22 g, 30%. Mp 150–152 °C (EtOH/H₂O). ¹H NMR (300 MHz, DMSO-*d*₆): δ 2.39 (3H, s, CH₃), 3.74 (OCH₃), 6.89 (2H, d, *J* = 9.0 Hz, H-3'' and H-5''), 7.02 (2H, brs, NH₂), 7.34–7.41 (2H, m, H-4' and H-5'), 7.71 (2H, d, *J* = 9.1 Hz, H-2'' and H-6''), 8.09–8.15 (2H, m, H-2' and H-6'), 9.34 (1H, s, NH); ¹³C NMR (75 MHz, DMSO-*d*₆): δ 21.0 (CH₃), 55.1 (OCH₃), 113.6 (C-3'' and C-5''), 121.6 (C-2'' and C-6''), 124.9 (C-2'), 128.1 (C-6'), 128.3 (C-5'), 131.8 (C-1''), 132.9 (C-4'), 136.8 (C-3'), 137.2 (C-1'), 154.5 (C-4''), 164.4 (C-2), 167.1 (C-4), 170.1 (C-6). Anal. calcd for C₁₇H₁₇N₅O: C, 66.43; H, 5.58; N, 22.79. Found: C, 66.34; H, 5.70; N, 22.64.

N²-(4-Isopropylphenyl)-6-(3-methylphenyl)-1,3,5-triazine-2,4-diamine (59)

Yield 0.36 g, 45%. Mp 134–136 °C (EtOH/H₂O). ¹H NMR (300 MHz, DMSO-*d*₆): δ 1.20 (6H, d, *J* = 6.9 Hz, (CH₃)₂), 2.40 (3H, s, CH₃), 2.85 (1H, m, *J* = 7.0 Hz, CH), 7.08 (2H, brs, NH₂), 7.17 (2H, d, *J* = 8.5 Hz, H-3'' and H-5''), 7.34–7.42 (2H, m, H-4' and H-5'), 7.75 (2H, d, *J* = 8.6 Hz, H-2'' and H-6''), 8.12–8.18 (2H, m, H-2' and H-6'), 9.44 (1H, s, NH); ¹³C NMR (75 MHz, DMSO-*d*₆): δ 21.0 (CH₃), 24.0 ((CH₃)₂), 32.8 (CH), 120.1 (C-2'' and C-6''), 125.0 (C-2'), 126.0 (C-3'' and C-5''), 128.1 (C-6'), 128.3 (C-5'), 131.9 (C-4'), 136.8 (C-3'), 137.2 (C-1'), 137.6 (C-1''), 142.0 (C-4''), 164.5 (C-2),

167.1 (C-4), 170.2 (C-6). Anal. calcd for C₁₉H₂₁N₅: C, 71.45; H, 6.63; N, 21.93. Found: C, 71.38; H, 6.69; N, 21.85.

N²-(4-Methoxyphenyl)-6-(4-methylphenyl)-1,3,5-triazine-2,4-diamine (65)

Yield 0.45 g, 60%. Mp 168–170 °C (EtOH). ¹H NMR (300 MHz, DMSO-*d*₆): δ 2.38 (3H, s, CH₃), 3.74 (3H, s, OCH₃), 6.90 (2H, d, *J* = 9.0 Hz, H-3'' and H-5''), 7.00 (2H, brs, NH₂), 7.30 (2H, d, *J* = 8.2 Hz, H-3' and H-5'), 7.71 (2H, d, *J* = 9.0 Hz, H-2'' and H-6''), 8.21 (2H, d, *J* = 8.1 Hz, H-2' and H-6'), 9.32 (1H, s, NH); ¹³C NMR (75 MHz, DMSO-*d*₆): δ 21.0 (CH₃), 55.1 (OCH₃), 113.6 (C-3'' and C-5''), 121.6 (C-2'' and C-6''), 127.7 (C-3' and C-5'), 128.8 (C-2' and C-6'), 132.9 (C-1''), 134.1 (C-1'), 141.1 (C-4'), 154.5 (C-4''), 164.5 (C-4), 167.1 (C-6), 170.0 (C-2). Anal. calcd for C₁₇H₁₇N₅O: C, 66.43; H, 5.58; N, 22.79. Found: C, 66.34; H, 5.66; N, 22.70.

N²,6-Bis(4-methoxyphenyl)-1,3,5-triazine-2,4-diamine (71)

Yield 0.30 g, 38%. Mp 163–165 °C (MeCN). ¹H NMR (300 MHz, DMSO-*d*₆): δ 3.74 (3H, s, OCH₃), 3.84 (3H, s, OCH₃), 6.90 (2H, d, *J* = 9.0 Hz, H-3'' and H-5''), 6.94 (2H, brs, NH₂), 7.05 (2H, d, *J* = 8.9 Hz, H-3' and H-5'), 7.71 (2H, d, *J* = 9.0 Hz, H-2'' and H-6''), 8.28 (2H, d, *J* = 8.9 Hz, H-2' and H-6'), 9.28 (1H, s, NH); ¹³C NMR (75 MHz, DMSO-*d*₆): δ 55.1 (OCH₃), 55.2 (OCH₃), 113.5 (C-3'' and C-5''), 113.6 (C-3' and C-5'), 121.6 (C-2'' and C-6''), 129.1 (C-1''), 129.5 (C-2' and C-6'), 133.0 (C-1'), 154.5 (C-4'), 161.8 (C-4''), 164.4 (C-4), 167.0 (C-6), 169.6 (C-2). Anal. calcd for C₁₇H₁₇N₅O₂: C, 63.15; H, 5.30; N, 21.66. Found: C, 63.02; H, 5.41; N, 21.57.

N²-(4-Fluorophenyl)-6-(4-(trifluoromethyl)phenyl)-1,3,5-triazine-2,4-diamine (84)

Yield 0.21 g, 28%. Mp 150–152 °C (EtOH). ¹H NMR (300 MHz, DMSO-*d*₆): δ 7.16 (2H, dd, ³*J*_{HF} = 8.9 Hz, ³*J*_{HH} = 8.9 Hz, H-3'' and H-5''), 7.29 (2H, brs, NH₂), 7.85 (2H, dd, ⁴*J*_{HF} = 5.1 Hz, ³*J*_{HH} = 9.1 Hz, H-2'' and H-6''), 7.90 (2H, d, ³*J* = 8.6 Hz, H-3' and H-5'), 8.50 (2H, d, *J* = 8.6 Hz, H-2' and H-6'), 9.70 (1H, s, NH); ¹³C NMR (75 MHz, DMSO-*d*₆): δ 114.9 (d, ²*J*_{CF} = 22.5 Hz, C-3'' and C-5''), 121.8 (d, ³*J*_{CF} = 7.5 Hz, C-2'' and C-6''), 124.1 (q, ¹*J*_{CF} = 271.5 Hz, CF₃), 125.3 (q, ³*J*_{CF} = 3.7 Hz, C-3' and C-5'), 128.4 (C-1'), 131.1 (q, ²*J*_{CF} = 31.6 Hz, C-4'), 136.1 (d, ⁴*J*_{CF} = 2.2 Hz, C-1''), 140.6 (q, ⁴*J*_{CF} = 1.5 Hz, C-2' and C-6'), 157.6 (d, ¹*J*_{CF} = 238.8 Hz, C-4''), 164.5 (C-4), 167.1 (C-6), 169.0 (C-2). Anal. calcd for C₁₆H₁₁F₄N₅O: C, 55.02; H, 3.17; N, 20.05. Found: C, 54.88; H, 3.26; N, 19.90.

N²-(4-Fluorophenyl)-6-(4-(trifluoromethoxy)phenyl)-1,3,5-triazine-2,4-diamine (91)

Yield 0.32 g, 58%. Mp 139–140 °C (EtOH). ¹H NMR (300 MHz, DMSO-*d*₆): δ 7.16 (2H, dd, ³*J*_{HF} = 8.9 Hz, ³*J*_{HH} = 8.9 Hz, H-3'' and H-5''), 7.22 (2H, brs, NH₂), 7.51 (2H, d, *J* = 8.0 Hz, H-3' and H-5'), 7.85 (2H, dd, ⁴*J*_{HF} = 5.0 Hz, ³*J*_{HH} = 9.0 Hz, H-2'' and H-6''), 8.42 (2H, d, *J* = 8.9 Hz, H-2' and H-6'), 9.64 (1H, s, NH); ¹³C NMR (75 MHz, DMSO-*d*₆): δ 114.9 (d, ²*J*_{CF} = 22.1 Hz, C-3'' and C-5''), 119.4 (q, ¹*J*_{CF} = 154.2 Hz, OCF₃), 120.5 (C-3' and C-5'), 121.7 (d, ³*J*_{CF} = 7.4 Hz, C-2'' and C-6''), 129.8 (C-2' and C-6'), 135.8 (C-1'), 136.1 (d, ⁴*J*_{CF} = 2.2 Hz, C-1''), 150.6 (q, ³*J*_{CF} = 1.5 Hz, C-4'), 157.5 (d, ¹*J*_{CF} = 239.0 Hz, C-4''), 164.5 (C-4), 167.1 (C-6), 169.0 (C-2). Anal.



calcd for $C_{16}H_{11}F_4N_5O$: C, 52.61; H, 3.04; N, 19.17. Found: C, 52.55; H, 3.21; N, 18.98.

6-(4-(Benzyloxy)phenyl)-*N*²-(4-fluorophenyl)-1,3,5-triazine-2,4-diamine (111)

Yield 0.53 g, 55%. Mp 177–179 °C (EtOH). ¹H NMR (300 MHz, DMSO-*d*₆): δ 5.19 (2H, s, CH₂), 7.07 (2H, brs, NH₂), 7.12–7.18 (4H, m, H-3', H-5', H-3'' and H-5''), 7.35–7.50 (5H, m, Ph), 7.86 (2H, dd, ⁴*J*_{HF} = 5.0 Hz, ³*J*_{HH} = 9.1 Hz, H-2'' and H-6''), 8.29 (2H, d, *J* = 8.9 Hz, H-2' and H-6'), 9.52 (1H, s, NH); ¹³C NMR (75 MHz, DMSO-*d*₆): δ 69.3 (CH₂), 114.4 (C-3' and C-5'), 114.8 (d, ²*J*_{CF} = 22.3 Hz, C-3'' and C-5''), 121.5 (d, ³*J*_{CF} = 7.4 Hz, C-2'' and C-6''), 127.7 (C-2''' and C-6'''), 127.9 (C-4'''), 128.4 (C-3''' and C-5'''), 129.2 (C-1'), 129.5 (C-2' and C-6'), 136.4 (d, ⁴*J*_{CF} = 2.2 Hz, C-1''), 136.7 (C-1'''), 157.3 (d, ¹*J*_{CF} = 238.5 Hz, C-4'') 161.0 (C-4'), 164.4 (C-4), 167.0 (C-6), 169.8 (C-2). Anal. calcd for C₂₂H₁₈FN₅O: C, 68.21; H, 4.68; N, 18.08. Found: C, 68.08; H, 4.80; N, 17.96.

*N*²-(2-Fluorophenyl)-6-(thiophen-2-yl)-1,3,5-triazine-2,4-diamine (116)

Yield 0.32 g, 45%. Mp 165–167 °C (EtOH/H₂O). ¹H NMR (300 MHz, DMSO-*d*₆): δ 7.09 (2H, brs, NH₂), 7.15–7.27 (4H, m, H-4', H-3'', H-4'' and H-5''), 7.72–7.78 (2H, m, H-5' and H-6''), 7.87 (1H, dd, *J* = 1.1 Hz, *J* = 3.6 Hz, H-3'), 9.04 (1H, s, NH); ¹³C NMR (75 MHz, DMSO-*d*₆): δ 115.5 (d, ²*J*_{CF} = 19.4 Hz, C-3''), 124.0 (d, ³*J*_{CF} = 3.7 Hz, C-6''), 125.5 (d, ³*J*_{CF} = 7.6 Hz, C-4''), 126.5 (d, ²*J*_{CF} = 11.9 Hz, C-1''), 126.6 (d, ⁴*J*_{CF} = 2.2 Hz, C-5''), 128.0 (C-4'), 129.2 (C-5'), 130.9 (C-3'), 142.4 (C-1'), 155.4 (d, ¹*J*_{CF} = 246.3 Hz, C-2''), 164.8 (C-4), 166.6 (C-6), 166.9 (C-2). Anal. calcd for C₁₃H₁₀FN₅S: C, 54.35; H, 3.51; N, 24.38. Found: C, 54.22; H, 3.75; N, 24.26.

*N*²-(2-Methoxyphenyl)-6-(thiophen-2-yl)-1,3,5-triazine-2,4-diamine (122)

Yield 0.43 g, 58%. Mp 165–167 °C (MeCN). ¹H NMR (300 MHz, DMSO-*d*₆): δ 3.87 (3H, s, OCH₃), 6.94–7.00 (1H, m, H-3''), 7.04–7.08 (2H, m, H-4'' and H-5''), 7.18 (2H, brs, NH₂), 7.21 (1H, dd, *J* = 3.7 Hz, *J* = 5.0 Hz, H-4'), 7.77 (1H, dd, *J* = 1.2 Hz, *J* = 5.0 Hz, H-5'), 7.92 (1H, dd, *J* = 1.3 Hz, *J* = 3.7 Hz, H-3'), 7.97 (1H, s, NH), 8.21 (1H, d, *J* = 7.3 Hz, H-6''); ¹³C NMR (75 MHz, DMSO-*d*₆): δ 55.7 (OCH₃), 110.9 (C-3''), 120.3 (C-5''), 121.8 (C-6''), 123.5 (C-4''), 127.7 (C-1''), 128.1 (C-4'), 129.3 (C-5'), 131.0 (C-3'), 142.3 (C-1'), 149.6 (C-2''), 164.2 (C-4), 166.6 (C-6), 166.9 (C-2). Anal. calcd for C₁₄H₁₃N₅OS: C, 56.17; H, 4.38; N, 23.40. Found: C, 56.08; H, 4.50; N, 23.26.

*N*²-(4-Methoxyphenyl)-6-(thiophen-2-yl)-1,3,5-triazine-2,4-diamine (123)

Yield 0.52 g, 70%. Mp 139–141 °C (EtOH/H₂O). ¹H NMR (300 MHz, DMSO-*d*₆): δ 3.74 (3H, s, OCH₃), 6.88 (2H, d, *J* = 9.0 Hz, H-3'' and H-5''), 7.06 (2H, brs, NH₂), 7.20 (1H, dd, *J* = 3.7 Hz, *J* = 5.0 Hz, H-4'), 7.70 (2H, d, *J* = 9.1 Hz, H-2'' and H-6''), 7.76 (1H, dd, *J* = 1.3 Hz, *J* = 5.0 Hz, H-5'), 7.89 (1H, dd, *J* = 1.3 Hz, *J* = 3.7 Hz, H-3'), 9.35 (1H, s, NH); ¹³C NMR (75 MHz, DMSO-*d*₆): δ 55.1 (OCH₃), 113.5 (C-3'' and C-5''), 121.6 (C-2'' and C-6''), 128.0 (C-4'), 129.0 (C-5'), 130.7 (C-3'), 132.8 (C-1''), 142.6 (C-1'), 154.5

(C-4''), 164.0 (C-4), 166.3 (C-6), 166.7 (C-2). Anal. calcd for C₁₄H₁₃N₅OS: C, 56.17; H, 4.38; N, 23.40. Found: C, 56.05; H, 4.54; N, 23.23.

Cytotoxicity evaluation

The cytotoxic activity of 6,*N*²-diaryl-1,3,5-triazine-2,4-diamines (1–126) was evaluated against three breast carcinoma cell lines (MDA-MB231, SKBR-3, and MCF-7) and normal breast cell line (MCF-10A) by MTT assay.²² All cells were obtained from the American Type Culture Collection and were grown in 10% fetal bovine serum and 1% pen-strep antibiotic supplemented media (DMEM for MDA-MB231 and SKBR-3, RPMI for MCF-7, and MEGM for MCF-10A). For MTT assay, 20 000 to 75 000 cells per mL (based on the doubling time for each cell line) were seeded in 96 well plates and incubated for 24 h at 37 °C in 5% CO₂ incubator. Then, compounds at different concentrations were added followed by the incubation at 37 °C for 72 h. After that, MTT solution (0.5 mg mL⁻¹) was added and the plates were incubated for another 4 h. The supernatant was then discarded and 100 μL of DMSO was added to each well. The plates were then read by Tecan NanoQuant (model: infinite m200 pro) plate reader and absorbance was measured at 570 nm. GI₅₀ values were calculated using sigmoidal concentration–response curves (see ESI†) generated using the GraphPad Prism 7 program. Three independent experiments were carried out and the data were represented as mean of the three experiments.

Building 3D-QSAR model

Out of 25 compounds, 19 compounds were utilized as a training set for building QSAR model. To assess reliability of the prepared model, an external validation was performed using remaining 6 compounds as a test set. The compounds were randomly divided into training and test set *via* 'Generate training and test set' module in Discover Studio v18. The selected test set included compounds 58, 73, 78, 99, 101, and 120.

For the model construction, the GI₅₀ values of the compounds on MDA-MB231 were converted to the negative logarithmic scale (pGI₅₀). The compounds were aligned to the minimum energy using the 'Align small molecules' protocol in the Discovery Studio. Steric (50%) and electrostatic (50%) fields were used to align the compounds.

In Discovery Studio, the CHARMM force field was used and the electrostatic potential and the van der Waals potential were treated as separate terms. A +1e point charge was used as the electrostatic potential probe and distance-dependent dielectric constant was used to mimic the solvation effect. For the van der Waals potential, a carbon atom with a 1.5 Å radius was used as a probe. The truncation for both the steric and electrostatic energies was set to 30 kcal mol⁻¹. The standard parameters implemented in Discovery Studio v18 were used. A Partial Least-Square (PLS) model was built using energy grids as descriptors. The QSAR model was built using the created 3D-QSAR protocol of Discovery Studio v18.



Conflicts of interest

There are no conflicts to declare.

Acknowledgements

This work is supported by the Ministry of Higher Education, Malaysia under the Fundamental Research Grant Scheme, grant number FRGS/1/2018/STG01/MUSM/02/2. The work is also partially supported by the Bridging Grant from the School of Pharmacy, Monash University Malaysia.

References

- 1 P. Singla, V. Luxami and K. Paul, Triazine as a promising scaffold for its versatile biological behavior, *Eur. J. Med. Chem.*, 2015, **102**, 39–57.
- 2 S. Cascioferro, B. Parrino, V. Spano, A. Carbone, A. Montalbano, P. Barraja, P. Diana and G. Cirrincione, 1,3,5-Triazines: a promising scaffold for anticancer drugs development, *Eur. J. Med. Chem.*, 2017, **142**, 523–549.
- 3 J. H. Silverberg and W. Dameshek, Use of triethylene melamine in treatment of leukemia and leukosarcoma, *JAMA*, 1952, **148**, 1015–1021.
- 4 J. R. Walsh, P. T. Pratt, W. E. Graham and H. J. Zimmerman, Treatment of leukemia and lymphomata with triethylene melamine, *Acta Haematol.*, 1954, **11**, 329–338.
- 5 P. G. Dymont, D. J. Fernbach and W. W. Sutow, Hexamethylmelamine (NSC-13875) for acute leukemia and solid tumors in children, *J. Clin. Pharmacol. New Drugs*, 1973, **13**, 111–113.
- 6 M. Karon, L. Sieger, S. Leimbrock, J. Z. Finklestein, M. E. Nesbit and J. J. Swaney, 5-Azacytidine: a new active agent for the treatment of acute leukemia, *Blood*, 1973, **42**, 359–365.
- 7 A. Aribi, G. Borthakur, F. Ravandi, J. Shan, J. Davison, J. Cortes and H. Kantarjian, Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia, *Cancer*, 2007, **109**, 713–717.
- 8 E. Jabbour, J.-P. Issa, G. Garcia-Manero and H. Kantarjian, Evolution of decitabine development: accomplishments, ongoing investigations, and future strategies, *Cancer*, 2008, **112**, 2341–2351.
- 9 E. S. Kim, Enasidenib: First global approval, *Drugs*, 2017, **77**, 1705–1711.
- 10 E. M. Stein, Enasidenib, a targeted inhibitor of mutant IDH2 proteins for treatment of relapsed or refractory acute myeloid leukemia, *Future Oncol.*, 2018, **14**, 23–40.
- 11 A. M. Venkatesan, C. M. Dehnhardt, E. Delos Santos, Z. Chen, O. Dos Santos, S. Ayril-Kaloustian, G. Khafizova, N. Brooijmans, R. Mallon, I. Hollander, L. Feldberg, J. Lucas, K. Yu, J. Gibbons, R. T. Abraham, I. Chaudhary and T. S. Mansour, Bis(morpholino-1,3,5-triazine) Derivatives: Potent Adenosine 5'-Triphosphate Competitive Phosphatidylinositol-3-kinase/Mammalian Target of Rapamycin Inhibitors: Discovery of Compound 26 (PKI-587), a Highly Efficacious Dual Inhibitor, *J. Med. Chem.*, 2010, **53**, 2636–2645.
- 12 M. Robert, R. F. Larry, L. Judy, C. Inder, D. Christoph, D. S. Effen, C. Zecheng, D. S. Osvaldo, A. K. Semiramis, V. Aranapakam and H. Irwin, Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor, *Clin. Cancer Res.*, 2011, **17**, 3193–3203.
- 13 B. J. Rhy, S. Kim, B. Min, K. Y. Kim, J. S. Lee, W. J. Park, H. Lee, S. H. Kim and S. Y. Park, Discovery and the structural basis of a novel p21-activated kinase 4 inhibitor, *Cancer Lett.*, 2014, **349**, 45–50.
- 14 M. Koh, J. C. Lee, C. Min and A. Moon, A novel metformin derivative, HL010183, inhibited proliferation and invasion of triple negative breast cancer cells, *Bioorg. Med. Chem.*, 2013, **8**, 2305–2313.
- 15 G. Miao, B. Liu, X. Guo, X. Zhang and G. Liu, Reduction behavior induced by HL010183, a metformin derivative against the growth of cutaneous squamous cell carcinoma, *Int. J. Clin. Exp. Pathol.*, 2015, **1**, 287–297.
- 16 A. Junaid, F. P. L. Lim, E. R. T. Tiekink and A. V. Dolzhenko, New one-pot synthesis of 1,3,5-triazines: three-component condensation, Dimroth rearrangement and dehydrogenative aromatization, *ACS Comb. Sci.*, 2019, **21**, 548–555.
- 17 A. Junaid and A. V. Dolzhenko, Microwave-assisted synthesis of 1,3,5-triazines: efficient approaches to therapeutically valuable scaffold, *Heterocycles*, 2019, **98**, 1678–1706.
- 18 D. L. Holliday and V. Speirs, Choosing the right cell line for breast cancer research, *Breast Cancer Res.*, 2011, **4**, 215.
- 19 *Discovery Studio Modeling Environment*, Biovia DS, Dassault Systems, San Diego, 2017.
- 20 M. Awasthi, S. Singh, V. P. Pandey and U. N. Dwivedi, Molecular docking and 3D-QSAR-based virtual screening of flavonoids as potential aromatase inhibitors against estrogen-dependent breast cancer, *J. Biomol. Struct. Dyn.*, 2015, **33**, 804–819.
- 21 B. Yang, Y. S. Yang, N. Yang, G. Li and H. L. Zhu, Design, biological evaluation and 3D QSAR studies of novel dioxin-containing pyrazoline derivatives with thiourea skeleton as selective HER-2 inhibitors, *Sci. Rep.*, 2016, **6**, 27571.
- 22 D. A. Scudiero, R. H. Shoemaker, K. D. Paull, A. Monks, S. Tierney, T. H. Nofziger, M. J. Currens, D. Seniff and M. R. Boyd, Evaluation of a Soluble Tetrazolium/formazan Assay for Cell Growth and Drug Sensitivity in Culture Using Human and Other Tumor Cell Lines, *Cancer Res.*, 1988, **48**, 4827–4833.

